The Checkup by Singlecare

NOVEMBER 2, 2023

GLP-1 (glucagon-like peptide-1) agonists, such as Ozempic and Wegovy, have been in the news because of their soaring popularity with celebrities for dramatic weight loss. So how do you know if they’re right for your patients (even those who aren’t diabetic)? These are the benefits of GLP-1 drugs , beyond blood sugar control.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

The Checkup by Singlecare

SEPTEMBER 7, 2023

Compare Mounjaro alternatives | Other GLP-1 receptor agonists | Oral biguanides | SGLT2 inhibitors | DPP4 inhibitors | GLP-1 receptor agonists for weight loss | Natural alternatives | How to switch meds Diet and exercise alone aren’t enough to control Type 2 diabetes. GLP-1 receptor agonists are relatively new on the U.S.

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

The Checkup by Singlecare

AUGUST 31, 2023

How to get Mounjaro without insurance Mounjaro (tirzepatide) is a brand-name prescription drug FDA-approved to control blood sugar levels in people with Type 2 diabetes. Some insurance plans and Medicare Part D drug plans cover Mounjaro for Type 2 diabetes, but some don’t. Is Mounjaro covered by insurance? mL of 5 mg/0.5

Insurance 98

Insurance Compounding Insurance Coverage Labelling 98

PharmaShots

JUNE 16, 2023

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40

FDA Labelling 40

PharmaShots

JUNE 9, 2023

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

FDA 40

FDA 40

PharmaShots

MARCH 17, 2023

5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years Date: Mar 15, 2023 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years Date: Mar 15, 2023 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted

FDA 40

FDA Labelling 40

PharmD Live

DECEMBER 21, 2021

With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag. Insulin, first introduced in 1921, 100 years later, 2021, diabetes monitoring devices are added to Medicare’s durable medical equipment list coverage. See it here.

FDA 52

FDA Hospitals 52

The Checkup by Singlecare

MAY 8, 2023

Still, widespread and uncontrolled prescribing in the 1990s triggered the first wave of an epidemic in the misuse and overdoses of specific types of analgesic medications known as opioids. Non-drug measures, such as exercise, ice, heat, massage, and weight loss, should be emphasized in managing any type of pain, as appropriate.

Controlled Substances 52

Controlled Substances Dosage Labelling FDA 52

The Checkup by Singlecare

MARCH 7, 2024

It was approved by the Food and Drug Administration (FDA) in 2017 for treating Type 2 diabetes. It’s a glucagon-like peptide-1 (GLP-1) receptor agonist, a glucose-lowering medicine. You may need up to 2 mg of Ozempic per week, depending on your diabetes management plan. The right dose is determined over time.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Packaging Insurance Coverage 52

The Checkup by Singlecare

MARCH 21, 2023

Pain management depends on adequately identifying the type of pain one is experiencing , which can be broken down into 4 broad categories: acute, chronic, neuropathic, and radicular pain. Lortab ( hydrocodone-acetaminophen ) is a type of opioid medication. mg to 2 mg every 4 hours as needed – adjust according to response IM, SubQ: 0.2

Dosage 52

Dosage Controlled Substances Labelling Packaging 52

PharmaShots

MARCH 10, 2023

Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes Date: Mar 10, 2023 | Tags: Vertex, VX-264, Type 1 Diabetes, Regulatory, US, FDA, IND Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies Date: Mar 10, 2023 | Tags: Alnylam, Medison Pharma, RNAi Therapies, Onpattro, patisiran, (..)

FDA 40

FDA Vaccines 40

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. million in Q3.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. million in Q3.

Insurance 98

Insurance Labelling Communication FDA 98